Acromegaly

Acromegaly Outlook Improves With Better Diagnostics and Treatment

Acromegaly Outlook Improves With Better Diagnostics and Treatment

By

With greater awareness, better therapeutics, and more precise imaging and biochemical assays, patients with acromegaly can be diagnosed and treated earlier and are oftentimes cured.

Early Manifestations, Sex Differences May Aid in Acromegaly Diagnosis

Early Manifestations, Sex Differences May Aid in Acromegaly Diagnosis

By

Researchers described signs and symptoms in the years prior to acromegaly diagnosis and reported on differences between men and women in their clinical manifestations.

High Prevalence of Sleep Apnea in Patients With Acromegaly

High Prevalence of Sleep Apnea in Patients With Acromegaly

By

Sleep apnea is common in patients with acromegaly and is often diagnosed before the diagnosis of acromegaly.

Updated Consensus on Management of Acromegaly Includes New Recommendations

Updated Consensus on Management of Acromegaly Includes New Recommendations

By

Experts in the management of acromegaly provide new recommendations on the medical management of acromegaly since the last published update in 2014.

Pasireotide Improves IGF-1 in Patients Resistant to Somatostatin Analogs

Pasireotide Improves IGF-1 in Patients Resistant to Somatostatin Analogs

By

Monthly pasireotide injections may benefit patients with acromegaly who are resistant to first-generation somatostatin analogs.

Screening for Comorbid Conditions Not Adequate in Acromegaly

Screening for Comorbid Conditions Not Adequate in Acromegaly

Investigators examined the frequency of comorbidity screening and the frequency of comorbidities in patients with acromegaly.

New Instrument Measuring Treatment Satisfaction May Benefit Patients With Acromegaly

New Instrument Measuring Treatment Satisfaction May Benefit Patients With Acromegaly

By

A new instrument may provide physicians insight into satisfaction with acromegaly treatment.

Acromegaly Diagnosis Delayed in Elderly Woman

Acromegaly Diagnosis Delayed in Elderly Woman

The presence of a pituitary tumor on magnetic resonance imaging confirmed the diagnostic hypothesis.

Signifor Earns FDA Approval for Acromegaly

Signifor Earns FDA Approval for Acromegaly

By

The FDA has approved pasireotide (Signifor long-acting release) for treatment of acromegaly.

Genetic Cause of Gigantism Explored

Genetic Cause of Gigantism Explored

By

Researchers have discovered a single gene in a region of the X chromosome that may cause excessive growth in children.

Endocrine Society Releases Guidelines for Acromegaly

Endocrine Society Releases Guidelines for Acromegaly

By

The Endocrine Society has issued a clinical practice guideline for the diagnosis and treatment of acromegaly.

ATL1103 Decreases IGF-1 in Acromegaly Trial

ATL1103 Decreases IGF-1 in Acromegaly Trial

In patients with acromegaly, ATL1103 significantly reduced serum insulin-like growth factor I (IGF-1) after 14 weeks of treatment.

Thyroid Cancer, Nodular Disease Risk Increased in Acromegaly

Thyroid Cancer, Nodular Disease Risk Increased in Acromegaly

Thyroid nodular disease and thyroid cancer prevalence appears to be higher in patients with acromegaly.

Mixed Metabolic Profiles Found in Acromegaly Remission

By

Some cardiovascular risk factors and adiposity increased during acromegaly remission.

Long-Acting Release Signifor Effective in Acromegaly Trial

Long-Acting Release Signifor Effective in Acromegaly Trial

Novartis announced results from a phase 3 trial for Signifor LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.

Sign Up for Free e-Newsletters



CME Focus